CR20150237A - Compuestos heteroaromáticos como ligandos de dopamina d1 - Google Patents
Compuestos heteroaromáticos como ligandos de dopamina d1Info
- Publication number
- CR20150237A CR20150237A CR20150237A CR20150237A CR20150237A CR 20150237 A CR20150237 A CR 20150237A CR 20150237 A CR20150237 A CR 20150237A CR 20150237 A CR20150237 A CR 20150237A CR 20150237 A CR20150237 A CR 20150237A
- Authority
- CR
- Costa Rica
- Prior art keywords
- heteroaromatic compounds
- dopamine ligands
- dopamine
- ligands
- heteroaromatic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Abstract
L a pres ent e in ve nc ió n p rop or c ion a, en p ar te, comp ue s to s d e la Fórmula I :
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723995P | 2012-11-08 | 2012-11-08 | |
| PCT/IB2013/059768 WO2014072882A1 (en) | 2012-11-08 | 2013-10-30 | Heteroaromatic compounds as dopamine d1 ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20150237A true CR20150237A (es) | 2015-07-01 |
Family
ID=49955424
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150237A CR20150237A (es) | 2012-11-08 | 2015-05-08 | Compuestos heteroaromáticos como ligandos de dopamina d1 |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US8822494B2 (es) |
| EP (1) | EP2917216B1 (es) |
| JP (1) | JP5823657B1 (es) |
| KR (1) | KR101660664B1 (es) |
| CN (1) | CN104837839A (es) |
| AP (1) | AP3861A (es) |
| AR (1) | AR095359A1 (es) |
| AU (1) | AU2013343105B2 (es) |
| BR (1) | BR112015010412A2 (es) |
| CA (1) | CA2889572C (es) |
| CL (1) | CL2015001233A1 (es) |
| CO (1) | CO7350619A2 (es) |
| CR (1) | CR20150237A (es) |
| EA (1) | EA201500402A1 (es) |
| ES (1) | ES2652514T3 (es) |
| GE (1) | GEP201606598B (es) |
| HK (1) | HK1213256A1 (es) |
| IL (1) | IL238712A0 (es) |
| MA (1) | MA38069A1 (es) |
| MD (1) | MD20150037A2 (es) |
| MX (1) | MX2015005506A (es) |
| NI (1) | NI201500066A (es) |
| PE (1) | PE20150966A1 (es) |
| PH (1) | PH12015500883A1 (es) |
| SG (1) | SG11201502884TA (es) |
| TN (1) | TN2015000167A1 (es) |
| TW (1) | TWI577678B (es) |
| UA (1) | UA111687C2 (es) |
| UY (1) | UY35129A (es) |
| WO (1) | WO2014072882A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010412A2 (pt) * | 2012-11-08 | 2017-07-11 | Pfizer | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 |
| EP2917219B1 (en) | 2012-11-08 | 2017-09-27 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| HUE062265T2 (hu) | 2013-06-27 | 2023-10-28 | Pfizer | Heteroaromás vegyületek és azok alkalmazása dopamin D1 ligandumokként |
| CA2946471C (en) | 2014-04-25 | 2018-08-07 | Pfizer Inc. | Fused bicyclic heteroaromatic compounds and their use as dopamine d1 ligands |
| MD20160109A2 (ro) | 2014-04-25 | 2017-04-30 | Pfizer Inc. | Compuşi heteroaromatici şi utilizarea lor ca liganzi ai dopaminei D1 |
| EP3134405B1 (en) | 2014-04-25 | 2019-08-28 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| US9856263B2 (en) | 2014-04-28 | 2018-01-02 | Pfizer Inc. | Heteroaromatic compounds and their use as dopamine D1 ligands |
| WO2015166366A1 (en) * | 2014-04-28 | 2015-11-05 | Pfizer Inc. | Heterocyclic compounds and their use as dopamine d1 ligands |
| CN103992319B (zh) * | 2014-05-27 | 2015-09-16 | 天津市斯芬克司药物研发有限公司 | 一种吡啶羧酸类化合物的制备方法 |
| CA3067591A1 (en) * | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
| MX2019015150A (es) | 2017-06-30 | 2020-08-13 | Chase Therapeutics Corp | Composiciones antagonistas de nk-1 y métodos para su uso en el tratamiento de la depresión. |
| PE20230838A1 (es) | 2020-06-22 | 2023-05-19 | Hoffmann La Roche | Derivados de sulfona |
| CN115340500A (zh) * | 2021-05-14 | 2022-11-15 | 广东东阳光药业有限公司 | 一种含硫化合物的制备方法 |
| WO2023143321A1 (zh) * | 2022-01-29 | 2023-08-03 | 苏州科睿思制药有限公司 | 他伐帕敦的晶型及其制备方法和用途 |
| CN114751855B (zh) * | 2022-05-23 | 2024-05-07 | 上海皓鸿生物医药科技有限公司 | 一种2-溴-4-氨基-5-甲基吡啶的制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US6395733B1 (en) | 1995-06-07 | 2002-05-28 | Pfizer Inc | Heterocyclic ring-fused pyrimidine derivatives |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| TW200400034A (en) | 2002-05-20 | 2004-01-01 | Bristol Myers Squibb Co | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors |
| SE0201980D0 (sv) | 2002-06-24 | 2002-06-24 | Astrazeneca Ab | Novel compounds |
| SE0301906D0 (sv) * | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
| US7132426B2 (en) | 2003-07-14 | 2006-11-07 | Arena Pharmaceuticals, Inc. | Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto |
| JP5368701B2 (ja) | 2004-07-02 | 2013-12-18 | エクセリクシス、インコーポレイテッド | ｃ−Ｍｅｔモジュレーター及び使用方法 |
| US7947676B2 (en) | 2004-12-14 | 2011-05-24 | Astrazeneca Ab | Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents |
| EP1841766A1 (en) | 2005-01-19 | 2007-10-10 | Biolipox AB | Pyrrolopyridines useful in the treatment of inflammation |
| US7880004B2 (en) | 2005-09-15 | 2011-02-01 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| WO2007081517A2 (en) | 2005-12-21 | 2007-07-19 | Abbott Laboratories | Anti-viral compounds |
| AU2007224020A1 (en) | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| US7601716B2 (en) | 2006-05-01 | 2009-10-13 | Cephalon, Inc. | Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors |
| WO2008037607A1 (de) | 2006-09-25 | 2008-04-03 | Basf Se | Carbonylgruppen-enthaltende heterocyclische verbindungen und deren verwendung zur bekämpfung von phytopathogenen pilzen |
| WO2008057402A2 (en) | 2006-11-02 | 2008-05-15 | Cytovia, Inc. | N-aryl-isoxazolopyrimidin-4-amines and related compounds as activators of caspases and inducers of apoptosis and the use thereof |
| US20080200458A1 (en) | 2007-01-18 | 2008-08-21 | Joseph Barbosa | Methods and compositions for the treatment of body composition disorders |
| US20080194557A1 (en) | 2007-01-18 | 2008-08-14 | Joseph Barbosa | Methods and compositions for the treatment of pain, inflammation and cancer |
| EP2137158A4 (en) | 2007-02-28 | 2012-04-18 | Methylgene Inc | LOW-MOLECULAR INHIBITORS OF PROTEINARGININE METHYLTRANSFERASES (PRMTS) |
| US8557830B2 (en) | 2007-06-07 | 2013-10-15 | Amgen Inc. | RAF kinase modulators and methods of use |
| US7829567B2 (en) | 2007-10-31 | 2010-11-09 | Kaohsiung Medical University | Imino-indeno[1,2-c] quinoline derivatives, their preparation processes, and pharmaceutical compositions comprising the same |
| EP2229381A1 (en) | 2007-12-06 | 2010-09-22 | Schering Corporation | Gamma secretase modulators |
| UY31984A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | DERIVADOS DE 1-(3,4-difluorobencil)-6-oxo-1,6-dihidropirimidin-5-carboxamidas N-sustituidas y de 2-(3,4-difluorobencil)-3-oxo-2,3-dihidro-1H-pirazol-4-carboxamidas N-sustituidas. |
| UY31982A (es) | 2008-07-16 | 2010-02-26 | Boehringer Ingelheim Int | Derivados de 1,2-dihidropiridin-3-carboxamidas n-sustituidas |
| CA2735368A1 (en) | 2008-09-10 | 2010-03-18 | Kalypsys Inc. | Aminopyrimidine inhibitors of histamine receptors for the treatment of disease |
| EP2331530B8 (en) | 2008-09-26 | 2013-12-25 | National Health Research Institutes | Fused multicyclic compounds as protein kinase inhibitors |
| MX2011009807A (es) * | 2009-03-19 | 2011-09-29 | Medical Res Council Technology | Compuestos. |
| WO2010118367A2 (en) | 2009-04-10 | 2010-10-14 | Progenics Pharmaceuticals, Inc. | Antiviral pyrimidines |
| EP2440048B8 (en) | 2009-06-09 | 2015-12-16 | NantBioScience, Inc. | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling |
| BR112012001325A2 (pt) | 2009-07-21 | 2017-05-02 | Gilead Calistoga Llc | tratamento de distúrbios do fígado com inibidaores de pi3k |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| GB201008134D0 (en) | 2010-05-14 | 2010-06-30 | Medical Res Council Technology | Compounds |
| US8299117B2 (en) | 2010-06-16 | 2012-10-30 | Metabolex Inc. | GPR120 receptor agonists and uses thereof |
| JP2013530238A (ja) | 2010-07-01 | 2013-07-25 | アムジエン・インコーポレーテツド | Ｐｉ３ｋ活性の阻害剤としての複素環化合物及びその使用 |
| CA2803624A1 (en) | 2010-07-02 | 2012-01-05 | Jason A. Duquette | Heterocyclic compounds and their use as inhibitors of pi3k activity |
| EP2917219B1 (en) * | 2012-11-08 | 2017-09-27 | Pfizer Inc | Heteroaromatic compounds and their use as dopamine d1 ligands |
| BR112015010412A2 (pt) * | 2012-11-08 | 2017-07-11 | Pfizer | compostos heteroaromáticos e seu uso como ligantes de dopamina d1 |
-
2013
- 2013-10-30 BR BR112015010412A patent/BR112015010412A2/pt not_active IP Right Cessation
- 2013-10-30 CA CA2889572A patent/CA2889572C/en active Active
- 2013-10-30 SG SG11201502884TA patent/SG11201502884TA/en unknown
- 2013-10-30 MX MX2015005506A patent/MX2015005506A/es unknown
- 2013-10-30 MD MDA20150037A patent/MD20150037A2/ro not_active Application Discontinuation
- 2013-10-30 KR KR1020157014721A patent/KR101660664B1/ko active IP Right Grant
- 2013-10-30 EP EP13820925.9A patent/EP2917216B1/en active Active
- 2013-10-30 CN CN201380063892.3A patent/CN104837839A/zh active Pending
- 2013-10-30 JP JP2015540249A patent/JP5823657B1/ja active Active
- 2013-10-30 ES ES13820925.9T patent/ES2652514T3/es active Active
- 2013-10-30 AU AU2013343105A patent/AU2013343105B2/en not_active Ceased
- 2013-10-30 GE GEAP201313820A patent/GEP201606598B/en unknown
- 2013-10-30 EA EA201500402A patent/EA201500402A1/ru unknown
- 2013-10-30 WO PCT/IB2013/059768 patent/WO2014072882A1/en active Application Filing
- 2013-10-30 AP AP2015008382A patent/AP3861A/en active
- 2013-10-30 PE PE2015000612A patent/PE20150966A1/es not_active Application Discontinuation
- 2013-10-30 UA UAA201504509A patent/UA111687C2/uk unknown
- 2013-11-05 US US14/072,563 patent/US8822494B2/en active Active
- 2013-11-07 AR ARP130104095A patent/AR095359A1/es unknown
- 2013-11-07 TW TW102140555A patent/TWI577678B/zh not_active IP Right Cessation
- 2013-11-08 UY UY0001035129A patent/UY35129A/es not_active Application Discontinuation
-
2014
- 2014-07-23 US US14/339,123 patent/US9133190B2/en active Active
-
2015
- 2015-04-21 PH PH12015500883A patent/PH12015500883A1/en unknown
- 2015-04-30 TN TNP2015000167A patent/TN2015000167A1/fr unknown
- 2015-05-05 MA MA38069A patent/MA38069A1/fr unknown
- 2015-05-07 CL CL2015001233A patent/CL2015001233A1/es unknown
- 2015-05-07 NI NI201500066A patent/NI201500066A/es unknown
- 2015-05-07 IL IL238712A patent/IL238712A0/en unknown
- 2015-05-08 CO CO15105499A patent/CO7350619A2/es unknown
- 2015-05-08 CR CR20150237A patent/CR20150237A/es unknown
- 2015-08-06 US US14/819,541 patent/US9527843B2/en active Active
-
2016
- 2016-02-02 HK HK16101174.8A patent/HK1213256A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150237A (es) | Compuestos heteroaromáticos como ligandos de dopamina d1 | |
| CR20140463A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CO7151548A2 (es) | Picolinamidas macrocíclicas como fungicidas | |
| EA201590321A1 (ru) | Дейтерированный барицитиниб | |
| PH12015502546B1 (en) | 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient | |
| EP2935264A4 (en) | BICYCLIC 1,4-PYRIDONE HETEROARYL COMPOUNDS | |
| EP2935214A4 (en) | 1,4-pyridone COMPOUNDS | |
| EP2681216A4 (en) | SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS | |
| UY34811A (es) | Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1 | |
| CR20150271A (es) | Peptidos como agonistas de oxitocina | |
| EP2857397A4 (en) | CONDENSED HETEROCYCLIC COMPOUND | |
| BR302012003837S1 (pt) | Configuracão aplicada a sola de calçado | |
| EP2889291A4 (en) | HETEROCYCLIC CONNECTION | |
| HK1204786A1 (zh) | 部分飽和的含氮雜環化合物 | |
| EA201590296A1 (ru) | Дейтерированный ибрутиниб | |
| EP2933247A4 (en) | HETEROCYCLIC CONNECTION | |
| IN2012DE00621A (es) | ||
| IN2015DN01061A (es) | ||
| EP2873669A4 (en) | HETEROCYCLIC CONNECTION | |
| EP2818473A4 (en) | HETEROCYCLIC CONNECTION | |
| EP2857400A4 (en) | HETEROCYCLIC CONNECTION | |
| EP2927229A4 (en) | Heterocyclic compound | |
| GB201318886D0 (en) | Improvements i or relating to organic compounds | |
| IN2012DE00620A (es) | ||
| DOP2015000060A (es) | Profármacos de aminoquinazolina inhibidora de cinasa |